Our platform combines machine learning and structural biology to identify conserved viral epitopes—regions that cannot mutate without rendering the pathogen nonfunctional. By focusing on these "Achilles’ heels," we create vaccines that remain effective even as viruses evolve.
We engineer self-assembling nanoparticles that present multiple conserved antigens simultaneously, training the immune system to recognize diverse variants. This approach mimics natural infection, triggering stronger, longer-lasting responses than traditional methods.
Our proprietary SMART-Adjuvant™ dynamically enhances immune activation based on the target pathogen, minimizing side effects while maximizing protection.
The modularity of our platform allows us to pivot quickly—developing new vaccine candidates in weeks, not years, for emerging threats.
Universal vaccines for influenza, coronaviruses, HIV, and other high-mutation pathogens.
Livestock vaccines to prevent zoonotic spillover and secure global food supplies.
A platform built to stop the next outbreak before it starts.
Our science is backed by Helix Capital Partners and Pandora Impact Capital, with collaborations across top research institutions.